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Abstract 
Neuroscience and Neurobiology have historically been neuron biased, yet up to 40% of the 
cells in the brain are astrocytes. These cells are heterogeneous and regionally diverse but 
universally essential for brain homeostasis. Astrocytes regulate synaptic transmission as part 
of the tripartite synapse, provide metabolic and neurotrophic support, recycle 
neurotransmitters, modulate blood ﬂow and brain blood barrier permeability and are 
implicated in the mechanisms of neurodegeneration. Using pluripotent stem cells (PSC), it is 
now possible to study regionalised human astrocytes in a dish and to model their contribution 
to neurodevelopmental and neurodegenerative disorders. The evidence challenging the 
traditional neuron-centric view of degeneration within the CNS is reviewed here, with focus 
on recent ﬁndings and disease phenotypes from human PSC-derived astrocytes. In addition 
we compare current protocols for the generation of regionalised astrocytes and how these can 
be further reﬁned by our growing knowledge of neurodevelopment. We conclude by 
proposing a functional and phenotypical characterisation of PSC-derived astrocytic cultures 
that is critical for reproducible and robust disease modelling. 
 
 
 
 
INTRODUCTION 
 
Astrocytes are the most important neural cell type in the management 
of homeostatic conditions in the brain (19). They are a type of glia in 
the central nervous system (CNS), together with oligodendrocytes 
and microglia. In the adult brain each astrocyte can contact up to a 
million individual synapses (68). Dendritic spines and presynaptic 
terminals are intimately wrapped by perisynaptic astrocytic processes 
forming the tripartite synapse; allowing astrocytes to respond to syn- 
aptic activity and in turn regulate synaptic transmission (6, 130). 
Recent studies have shown that the cellular composition of the 
human brain is different to what has been taught for over half a cen- 
tury [for review see (15)]. Historically, the human brain was believed 
to contain roughly one trillion glial cells and 100 billion neurons 
yielding a glia to neuron ratio of 10:1. The neurons were thought to 
be the “talented tenth” due to their ability to communicate via electri- 
cal activity and hence perform long distance communication. This 
exceptional property, not attributable to glia, may in part explain our 
fascination with neurons and the many in depth studies carried out on 
neurons in relation to their degeneration. More recently Herculano- 
Houzel and colleagues have developed and validated an isotropic 
fractionator method which demonstrated a 1:1 ratio of glia to neurons 
and hence a glial cell total of 100 billion (74); much lower than previ- 
ously thought. Whilst astrocytes are known to comprise of up to 40% 
of all cells within the brain (73), there are regional differences in their 
numbers;  for  example,  neurons  outnumber  astrocytes  in  the 
cerebellum while the opposite is true in the cortex (73). Such regional 
differences highlight an important consideration of their potential 
role in disease pathogenesis. 
Astrocytes are a heterogeneous population of cells that have dif- 
ferent morphological and physiological characteristics. Tradition- 
ally, they are classiﬁed into two main subtypes depending on their 
location within the CNS; protoplasmic astrocytes are mainly found 
in grey matter and ﬁbrous astrocytes in the white matter (117). 
However, more recent evidence suggests that this classiﬁcation 
is oversimpliﬁed and that astrocyte heterogeneity may be an 
underappreciated topic in neurobiology [for review see (176)], a 
view supported by a growing number of genomic studies (76, 
174). Despite their heterogeneity, it is well established that 
astrocytes play pan-neural roles in cell to cell communication, 
metabolic support and also in neurotransmitter recycling (134, 
144). In addition to their supportive roles, astrocytes have also 
been shown to control the formation, function and removal of 
synapses (53, 131), they also are important in the control of blood 
ﬂow and critical for the maintenance of the blood brain barrier 
(BBB) (13, 80, 87, 103). 
 
 
WHY  STUDY ASTROCYTES? 
 
There is an accumulating body of evidence that astrocytes medi- 
ate many homeostatic processes which allows us to challenge the 
traditional neuron-centric view of degeneration within the CNS. 
  
 
 
The concept of reactive astrogliosis and its molecular and cellu- 
lar deﬁnition are still incomplete and we are only really starting 
to understand the multifaceted roles of astrocytes in disease [for 
review see (18, 133)]. Nevertheless, it is becoming increasingly 
clear that astrocytic function contributes to the initiation and/or 
progression of neuronal loss. As reviewed below, multiples stud- 
ies offer compelling evidence of non-cell autonomous astrocyte 
dependent mechanisms both in neurodegenerative and neurode- 
velopmental disorders. 
 
Alzheimer’s disease 
 
Alzheimer’s disease (AD) —the most common cause of demen- 
tia—is characterized by three pathological features: neuroﬁbrillary 
tangles consisting of intracellular inclusions of hyperphosphory- 
lated tau, extracellular deposits of amyloid beta (Ab) also known 
as amyloid plaques, and vascular amyloidosis. The exact mecha- 
nisms of action are still a topic of debate, however, accumulation of 
the Ab  peptide is believed to result in neuronal dysfunction and 
eventually cell death (148). Mutations in the amyloid precursor pro- 
tein gene (APP), APP triplications—as seen in Down Syndrome— 
or mutations in the APP processing machinery (PSEN-1 & PSEN- 
2) cause early onset AD [EOAD for review see (54)]. These ﬁnd- 
ings led to the amyloid hypothesis and to a neuronal focus in AD 
research. 
The ﬁrst evidence that astrocytes play an active role in the patho- 
genesis was provided by Wyss-Corey and colleagues in 2003. 
These authors utilized mouse astrocytes to show that they could 
both take up and degrade Ab (172). This followed on from work 
that had shown the presence of Ab within astrocytes in the human 
brain (59, 163) and reactive astrocytosis surrounding amyloid pla- 
ques (123). We now know that astrocytes can release a full arsenal 
of amyloid cleaving enzymes including neprelysin, endothelin con- 
verting enzyme-2 and angiotensin-converting enzyme-1 (135). A 
recent study by Liao et al demonstrated at single cell level that 
human induced pluripotent stem cells (hiPSC) derived astrocytes 
can secrete relatively high levels of Ab (101). Astrocytes and not 
just neurons are also affected by Ab. For example, Ab treatment 
leads to an increase in intracellular Ca21  in rat astrocytes but not 
neurons. This causes glutathione depletion and astrocytic death fol- 
lowed only indirectly by neuronal loss (2). Ab also causes the 
release of inﬂammatory cytokines (IFN-g, IL-1b and IL-6) and 
astrocyte activation (61). Moreover, astroglyosis can occur in the 
absence of Ab-plaques (153) and in rat mixed cultures Tau- 
hyperphosporylation requires the presence of astrocytes (61), indi- 
cating that the astrocyte involvement in AD goes beyond amyloid. 
Disease phenotypes have also been conﬁrmed in human astrocytes 
from familial and sporadic cases. Jones et al found aberrant mor- 
phology and pronounced pathological phenotypes in AD-astrocytes 
(82), while Kondo et al reported increased endoplasmic reticulum 
and oxidative stress associated with intracellular Ab in hiPSC 
derived astrocytes and neurons (89). 
Nevertheless, EOAD represents a very small proportion of AD 
cases and interestingly the genes implicated in Late Onset AD 
(LOAD) are not speciﬁcally neuronal. A GWAS by Harold et al 
identiﬁed three loci associated with AD: ApoE, Clusterin and PIC- 
ALM (70). PICALM is mainly expressed in endothelial cells from 
blood vessels in the brain, whereas Clusterin and ApoE (Xu et al, 
2006)  are  typically  astrocytic genes.  ApoE  is  a  lipid  binding 
protein, highly expressed in the CNS and the best studied risk fac- 
tor for LOAD. ApoE is expressed predominantly in astrocytes but 
also in neurons that have undergone injury or stress (23, 50, 110). 
The human ApoE gene is polymorphic, encoding one of 3 isoforms 
E2, E3 or E4, which differ by just 2 amino acids, producing sub- 
stantial isoform-speciﬁc properties (111). Unlike genetic mutations 
that cause autosomal dominant forms of AD, the role of ApoE is 
more complex (157). Different ApoE alleles modify the risk of 
developing AD. ApoE3—the most common allele is considered the 
normal version of ApoE. ApoE4 is associated with an increased 
risk of AD—5 times for heterozygous and 14 times for homozy- 
gous compared to carriers of E3 (43). Interestingly over 65% of 
AD patients carry a copy of ApoE4. The relationship between 
ApoE and AD has been attributed to the ability of ApoE to bind 
Ab  for clearance, and its role in transporting lipids for neuronal 
homeostasis and synaptogenesis (110). The role of ApoE in Ab 
clearance is attributed in part to the physiology of astrocytes, which 
internalize and degrade Ab (23). Indeed, astrocytes are associated 
with Ab plaque degradation and their ability to localize to the pla- 
ques requires ApoE (23, 86). Astrocytes from ApoE knockout mice 
lack this ability while upregulation of ApoE in an Ab over express- 
ing mouse model reversed their AD-like phenotype (23, 88). This 
suggests that enhancement of astrocyte mediated clearance of Ab 
is a promising therapeutic target for the treatment of AD, and from 
work in animal models it is clear that ApoE is fundamental to this 
process (9, 45, 88). 
It is possible that the ﬁrst alterations leading to AD do not take 
place in neurons but elsewhere. Indeed, early vasculature changes 
in endothelial permeability are thought to precede any neurological 
symptom (30). Interestingly, we know that BBB-function is regu- 
lated by the cross-talk between astrocytes and endothelial cells [for 
review see (1)] and that astrocyte secreted ApoE the biggest genetic 
risk factor for LOAD is essential to maintain BBB permeability 
(16). Thus, suggesting that to understand the pathological mecha- 
nisms in AD we must look beyond the dying neurons and possibly 
even beyond astrocytes. 
 
Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most common neurodege- 
nerative disease and is characterized by bradykinesia, tremor, rigid- 
ity and postural instability. The etiology of this disease is largely 
unknown, but it involves a complex interaction between various 
genetic and environmental factors. To date 17 distinctive chromo- 
somal locations or PARK genes (PARK (1–18)) have been identi- 
ﬁed in familial PD cases. Although only 10% of PD cases are 
familial, recent GWAS studies have also detected a role for genetic 
variants in sporadic PD [for review see (58, 96)]. Neuropathologi- 
cally, there is loss of dopaminergic neurons in the substantia nigra 
and also Lewy bodies within surviving neurons which are com- 
posed of a-synuclein (156). However, the reduced glutathione lev- 
els, mitochondrial damage and accumulation of extracellular toxins 
seen in PD (81) also indicate astrocyte dysfunction. 
Mutations and multiplications of the SNCA gene are associated 
with familial PD and cause early disease onset. Furthermore, the 
spread of a-synuclein pathology can be used to stage the disease 
progression (24) and some studies have suggested a prion-like 
propagation of a-synuclein [for review see (35)]. This occurs not 
just from neuron to neuron but also from neuron to astrocytes (97), 
  
 
 
with the toll like receptor 4 (TLR4) pathway implicated in the 
uptake of a-synuclein in astrocytes (57, 138). Indeed, there are a 
plethora of animal based studies that have implicated astrocytes in 
PD pathogenesis. The gene that has been most extensively studied 
is DJ-1, which is encoded by Park-7. DJ-1 knockdown in astro- 
cytes results in decreased protection of neurons; for example, 
impaired protection against the neurotoxins rotenone (121) and 6- 
OHDA (98). In addition, its mutation alters the expression of proin- 
ﬂammatory  mediators,  TNF-a   and  prostaglandin  E2  (PGE2), 
which may provide decreased neuroprotection to surrounding neu- 
rons (7) Interestingly, Neumann and colleagues demonstrated that 
the DJ-1 protein was up-regulated in reactive astrocytes in the 
human post-mortem Parkinsonian brain with little expression in 
intra neuronal a-synuclein inclusions (127), suggesting that astro- 
cytes may be involved in neurodegeneration associated with this 
mutation. 
LRRK2 mutations are the most common cause of familial PD 
(41) and polymorphisms in the LRRK2 locus have been associated 
with an increased risk of PD (175). Indeed the function of this pro- 
tein has been intensely studied (42, 49, 64, 115, 169). Pathogenic 
mutations produce enlarged lysosomes with reduced degradative 
capacity (72) and are linked to the accumulation of a-synuclein 
(102). 
PINK-1 and Parking have been widely implicated in mitophagy 
(91). Mutations in these genes lead to autosomal recessive PD. 
Relating to their role in astrocyte biology PINK1 expression has 
been shown to increase during stem cell differentiation and brain 
development and also to affect the development of GFAP positive 
astrocytes (38). In addition, a deﬁciency in PINK1 impedes astro- 
cyte proliferation through mitochondrial dysfunction and EGFR 
downregulation (39). Similarly, glial dysfunction has also been 
reported in Parkin null mice and midbrain cultures from Parkin 
mutant mice are resistant to oxidative stress (154, 155). 
 
Amyotrophic lateral sclerosis 
 
Amytrophic lateral sclerosis (ALS) is a devastating and rapidly pro- 
gressing neurodegenerative condition caused by the degeneration 
of neurons in the motor cortex, brain stem and spinal cord resulting 
in muscle paralysis and ultimately motor neuron death (85, 145). 
Most of ALS cases are sporadic, with around 10% of familial cases 
[for review see (161)]. ALS is perhaps the neurodegenerative dis- 
ease where the non-cell autonomous contribution of astrocytes to 
disease mechanisms has been best established. Early studies showed 
selective loss of the astrocyte glutamate transporter GLT-1 (143) and 
markedly reduced glutamate uptake in post-mortem ALS tissue (81). 
Accordingly, knockout of astrocytic GLT-1 leads to excitotoxicity 
and neurodegeneration in mice (141). Astrocyte pathology, 
preceding motor neuron degeneration has also been reported in 
animal models of SOD1-ALS (48). Multiple in vitro studies have 
conﬁrmed the importance of astrocytes in ALS. For example, 
human HB9 positive motorneurons degenerate when co- 
cultured on  primary cortical astrocytes carrying the  SOD1G93A 
mutation. This effect was speciﬁc to SOD1G93A  astrocytes as over- 
expression of wild-type SOD1 or co-culture with SOD1G93A  mouse 
embryonic ﬁbroblasts had no effect on motorneuron cell numbers. 
Non-cell autonomous toxicity occurred even in the absence of glial 
SOD1 inclusions and was partly mediated by increased release of 
the  pro-inﬂammatory  cytokine  PGD2  (48).  Using  a  similar 
approach Marchetto et al reported nearly 50% motorneuron loss in 
co-cultures with primary astrocytes overexpressing mutant 
SOD1G73R.  Interestingly, the effect was motorneuron speciﬁc as 
other neuronal cell types in the dish—such as GABA1   neurons 
were not affected (113). More recent studies have extended the 
involvement of astrocytes beyond SOD1-ALS. Almad et al found 
increased Connexin 43 expression, astrocyte coupling and intracel- 
lular calcium not only in SOD1G93A  astrocytes but also in C9ORF72 
expansion carriers and sporadic cases of ALS (4); a tan- talizing 
ﬁnding that would make Connexin 43 and astrocytes a cen- tral node 
in the pathophysiological mechanisms for multiple ALS subtypes. 
From the TDP43-ALS side we know that mutations in the 
TARDBP gene—which encodes TDP-43—affect the survival of 
hiPSC-derived neurons and astrocytes (11), with increased cyto- 
plasmic levels of TDP-43 leading to over twofold increase in the 
risk of cell death in TARDBPM337V astrocytes (149). This conﬁrms 
that the nuclear-cytoplasmic ratio of TDP-43 must be ﬁnely tuned 
not just in neurons but also in astrocytes. Interestingly, 
TARDBPM337V astrocytes had no direct effect on the survival of 
wild-type motorneurons (149), which would suggest that—unlike 
the case of SOD1—the ALS mechanisms mediated by TDP-43 
appear to be largely cell autonomous. Furthermore, mutations in 
the MAPT locus associated with Fronto-Temporal Dementia lead to 
astrocyte pathology in vitro—with hypertrophy, increased 4R-Tau 
expression and exacerbated sensitivity to oxidative damage in 
human MAPTN279K astrocytes (69). This is important because ALS 
and FTD are considered part of the same disease continuum and 
together, these data implicate astrocytes all the way from pure 
SOD1-ALS to the MAPT associated FTD spectrum. 
 
Huntington’s disease 
 
Huntington disease (HD) is caused by a trinucleotide expansion in 
the Huntingtin gene located in chromosome 4. Huntingtin (HTT) is 
ubiquitously expressed and mutant HTT has been shown to accu- 
mulate both in human neurons and astrocytes (55). Multiple mecha- 
nisms have been proposed to explain the preferential loss of striatal 
medium spiny neurons (MSN) in HD. These include glutamate 
excitotoxicity, oxidative stress, mitochondrial dysfunction and loss 
of neurotrophic factor support—for review see (63). That astrocytes 
are an integral part of these, is becoming increasingly clear. For 
example, transgenic mice, expressing mutant HTT under the GFAP 
promoter show age-dependent behavioral phenotypes, reduced 
EAAT1 expression and reduced striatal glutamate uptake—albeit 
no MSN loss (25). In the R6/2 mouse model of HD, striatal astro- 
cytes have lower K1  conductance and reduced Kir4.1 potassium 
channel expression and of these 20% display mHTT nuclear inclu- 
sions. Lower K1 conductance in astrocytes leads to higher extracel- 
lular K1  concentration and increased depolarization and excitability 
of MSN (164). This occurs before any evident signs of gliosis. 
Remarkably, restoring astrocytic Kir4.1 levels by viral delivery 
attenuated the disease phenotypes in R6/2 mice—improv- ing motor 
phenotypes and prolonging life-span (164). From another angle, loss 
of BDNF expression and neurotrophic support has also been linked 
to HD (179). BDNF is produced by both neurons and astrocytes and, 
at least in mice, expression of mHTT has been shown to impair 
astrocytic BDNF secretion (77). Furthermore, expression of mHTT 
in mouse astrocytes causes loss of wild-type 
  
 
 
neurons in co-cultures in vitro (152). Whether these ﬁndings hold 
true for human astrocytes and neurons remains to be investigated. 
To our knowledge only one study has explored disease phenotypes 
in human astrocytes derived from HD hiPSC lines. Juopperi et al, 
reported increased vacuolization in the cytoplasm of astrocytes 
expressing  109CAG-mHTT—compared to  control  28CAG-HTT 
cells (83). However, the signiﬁcance of this ﬁnding or how this 
affects astrocytic function in HD is unclear. 
 
 
Down’s syndrome 
 
Down Syndrome (DS) is a neurodevelopmental disorder caused by 
trisomy of chromosome 21. Besides being the most common cause 
of intellectual disability, DS is also associated with a much higher 
risk of developing early onset AD. The APP locus is located in the 
chromosome 21 (21q21.3). Therefore, trisomy causes continuous 
overproduction of amyloid, leading to development of neuroﬁbril- 
lary tangles and amyloid plaque pathology by the age of 40. By the 
age of 60, more than 60% of DS sufferers will develop dementia 
(171). 
In addition to the traditional difﬁculty of studying developing 
human neural cells, modeling full chromosome 21 trisomy is not 
possible in mice, which has hindered DS research. This makes 
hiPSC-technology particularly attractive for the study of DS. More- 
over, as there is a small degree of mosaicism in DS ﬁbroblasts, it is 
possible to generate euploid and aneuploid hiPSCs clones from the 
same affected individual (168). It is also possible to generate 
euploid subclones from otherwise karyotypically stable trisomic 
hiPSC lines (109). This means that obtaining isogenic control 
lines—critical for a multilocus disorder such as DS—is relatively 
straightforward. Despite early studies implicating glial pathology— 
including reactive astrogliosis and upregulation of S100b and IL-1 
(65) research in DS has focused on neuronal dysfunction. Shi et al 
found intracellular aggregation of Ab42 and tau hyperphosphoryla- 
tion associated with increased cell death in cortical neurons derived 
from 21-trisomic hiPSCs (151), while Weick et al reported 
increased oxidative stress vulnerability and reduced ability to form 
functional synapses in these neurons (168). A study by Briggs et al 
conﬁrmed the sensitivity of these neurons to oxidative stress but 
interestingly also found a two-fold bias in neural differentiation 
towards glial lineages—given by the number of GFAP1  cells—as 
well as increased expression of other astroglial genes including 
EAAT1, S100b and NF1A (27). Of note, the S100b genomic locus 
21q22 is also triplicated in DS and it is known that S100b overex- 
pression can cause gliosis (119) and stimulate iNOS expression 
(78). In an elegant study, Chen et al conﬁrmed a higher expression 
of S100b and iNOS in hiPSC-derived DS-astrocytes compared to 
isogenic disomic controls. These astrocytes showed faster prolifera- 
tion rates, increased production of reactive oxygen species and NO, 
together with reduced ApoE, BDNF, Nrf2, Tsp-1 and Tsp-2 expres- 
sion, suggesting a shift from a neuroprotective/neurotrophic proﬁle 
towards a more pro-inﬂammatory/neurotoxic phenotype. Accord- 
ingly, S100b knockdown or pharmacological treatment with the 
anti-inﬂammatory and anti-oxidant antibiotic minocycline were 
able to partially revert these phenotypes. Together, these data indi- 
cate that early glial alterations could underlie the developmental 
effects seeing in DS. 
Other neurodevelopmental disorders 
 
Rett syndrome is a rare neurodevelopmental disorder caused by 
mutations in the methyl-CpG-binding protein 2 (MeCP2) gene 
located in the X-chromosome. A DNA binding protein, MeCP2 
has been involved in transcriptional activation, transcriptional 
repression, retrotransposon silencing  and  chromatin remodeling 
[for review see (107)]. hiPSC are particularly well suited for Rett- 
syndrome modeling: X-chromosome reactivation during hiPSCs 
reprogramming followed by random inactivation during somatic 
cell differentiation means that it is possible to generate quasi- 
isogenic lines from heterozygous female carriers. Furthermore, 
because MeCP2 functions are not restricted to neurons, it is impor- 
tant to proﬁle MeCP2 mutations in all neural cell types. Indeed, 
non-cell autonomous effects of MeCP2 mutations on dendritic mor- 
phology have been reported in mouse astrocytes (10). Similarly, 
human neurons co-cultured with hiPSC-derived astrocytes carrying 
MeCP2  mutations  are  morphologically  abnormal—showing 
reduced somas, neurite length and branching (170). Altered microtu- 
bule dynamics, increased non-directional movement of lysosomal 
vesicles has also been reported in hiPSC-derived MeCP2R294X 
astrocytes (47). These phenotypes could be recovered with Epothi- 
lone D, a microtubule stabilizing drug (47), highlighting the poten- 
tial of hiPSC-astrocyte modeling to uncover novel pharmacological 
targets for this condition. 
Alexander’s disease is an extremely rare neurodevelopmental 
condition, with only around 500 cases described to date. Symptoms 
typically appear before the age of two and include megalencephaly, 
seizures, stiffness and intellectual disability. Histopathologically, 
the disease is characterized by the presence of Rosenthal ﬁbers in 
astrocytes—intracellular aggregates of  GFAP, HSP-27 and ab- 
crystallin [for review see (147)]. Astrocytes have been the focus of 
Alexander’s disease research since the discovery of causative domi- 
nant mutations in the GFAP gene (26), which made this condition 
the prototypical astrocytic genetic disorder. Clearly, modeling 
Alexander’s Disease in hiPSC derived astrocytes has great poten- 
tial. Especially since human astrocytes seem to show strong disease 
phenotypes, including Rosenthal-like GFAP aggregates, altered 
gene expression proﬁle an increased production of IL-5, IL-6 and 
TNF-a (90). 
 
 
THE POWER OF HUMAN IPS CELLS TO 
MODEL NEURODEGENERATIVE 
DISEASE AND 
NEURODEVELOPMENTAL DISORDERS 
 
To date, there have been many approaches to studying CNS dis- 
eases, which include classical cell lines such as HEK293, SHY5Y 
cells and primary cultures from rodents. Another avenue of research 
has utilised whole animal models, in particular rodents 
overexpressing proteins that play key roles in the disease. This 
research has been undeniably informative but has intrinsic ﬂaws. 
Most often the protein in question is present at much higher levels 
than would normally exist in the human brain. Furthermore, any 
non-human model of human disease is fundamentally limited; 
rodents do not develop AD, PD or DS, and this highlights crucial 
inter species differences. For these reasons it has been difﬁcult to 
translate ﬁndings into the clinic. Most strikingly various drugs that 
  
 
 
showed promise in animal models have failed human trials (32). 
Therefore, there is a requirement for a model where proteins 
involved in neurodegenerative and neurodevelopmental disorders 
are studied at native levels and in human cells, thus more closely 
recreating the environment of the human brain. iPS cell technology 
can generate “vulnerable” neural subtypes from patients with the 
disease offering an unprecedented insight into cell type speciﬁc 
pathology, something that cell lines and primary cultures cannot. In 
addition, as discussed above, neuropathological mechanisms 
involve interactions between neurons and glia which cannot be 
modelled by generating neurons alone. Furthermore, there is a long 
list of interspecies differences between rodent and human astrocytes 
which underlies the need for authentic human astrocytes for appro- 
priate disease modeling [for review see (34)]: (i) Human astrocytes 
are more complex than their rodent counterparts (128). (ii) Human 
astrocytes display twice as many processes as their rodent counter- 
parts (176). (iii) Two main astrocytes—proteoplasmic and ﬁbrous- 
types are found in the mouse brain while two additional subtypes 
have been identiﬁed in primates (40). (iv) This structural complex- 
ity is also reﬂected in functional properties: human astrocytes prop- 
agate calcium waves more rapidly than rodent counterparts and 
have a greater response to glutamate (158, 177). (v) There are strik- 
ing differences in their transcriptomic proﬁles, with over 600 genes 
expressed in human astrocytes that are not active in rodent astro- 
cytes (176). The potential of iPSC-derived astrocytes for disease 
modeling is illustrated in Table 2, which summarizes pathological 
mechanisms and disease phenotypes uncovered in these cells. 
 
 
ASTROCYTE DIFFERENTIATION— 
TAKING CUES FROM THE EMBRYO 
 
Due to the signiﬁcance of astrocytes in the CNS, their efﬁcient gen- 
eration from human pluripotent stem cells (hPSCs), is essential for 
disease modelling. To achieve the differentiation of hPSCs into the 
vast array of cell types of the CNS, researchers have looked to 
embryonic development to inform us of the cues required (105). In 
the embryo, the processes of cellular differentiation and regional 
patterning are tightly regulated and their correct speciﬁcation is key 
to generate a correctly functioning CNS. These must be recapitu- 
lated in vitro with hPSCs to accurately generate the speciﬁc func- 
tional cell populations. There are certain crucial requirements of 
hPSC differentiation protocols: (i) Acquisition of neural progenitor 
fate and loss of pluripotency; (ii) Regional patterning of the progen- 
itors, relating to the positional identity of the resulting mature cell 
population in the CNS; (iii) Successful generation the type of cell 
required; (iv) Characterization of the resulting cells to conﬁrm true 
identity and function. Here we will discuss how these principles are 
being met in relation to the generation of astrocytes from hPSCs. 
 
The acquisition of neural identity 
 
The ﬁrst event of cellular specialization in the embryo is differ- 
entiation of the three embryonic germ layers, mesoderm, endo- 
derm and ectoderm (106). The ectoderm gives rise to the 
neuroepithelium, which is composed of the neural progenitors 
that give rise to all specialized cells of the CNS. These early 
developmental events are recapitulated when differentiating 
hPSCs (114, 166). Many neural differentiation protocols utilize 
an Embryoid Body (EB) stage in the protocol—the EB is the 
established method to recapitulate and model early embryonic 
development using mouse or human Embryonic Stem Cells 
(ESCs) (114, 166). Using mechanical or enzymatic dissociation 
ESCs are seeded in 3D culture and form non-adherent spheres. 
Removing  the  factors required for  maintaining pluripotency, 
LIF for mouse and FGF signaling for human, results in sponta- 
neous differentiation of the three embryonic germ layers and 
subsequently their more specialized derivatives (166). Differen- 
tiation of hPSCs can also be achieved as a monolayer of adher- 
ent cells, and there has been somewhat of a division in the ﬁeld 
between  EB-based  vs.  monolayer  differentiation  (Table  1). 
Some would argue that differentiation of hPSCs as a monolayer 
may be easier to “program” as by its nature EB based differen- 
tiation recapitulates many of the endogenous signaling pathways 
of the early embryo. For directed differentiation of a single 
desired cell type these signaling pathways may yield undesirable 
effects generating unwanted cell types. However, EB based dif- 
ferentiation is still used very successfully by many labs as a 
basis for hPSC differentiation (Table 1). The ﬁeld has also seen 
the advent of chemically deﬁned media where every component 
is known and characterized, essentially providing a ‘blank can- 
vas’  for  unbiased  cell  differentiation  that  can  be  directed 
towards a desired fate (165). 
In the early embryo BMP and Nodal signaling inhibit neural dif- 
ferentiation (106). Nodal and BMP signal transduction occurs via 
SMAD proteins, and inhibition of SMADs has been adopted by the 
stem cell ﬁeld to enable differentiation of hPSCs into neural line- 
ages (166, 167). Chambers and colleagues ﬁrst published what they 
termed “dual SMAD inhibition,” using the small molecule inhibitor 
SB431542 to block Nodal signaling, and a recombinant form of the 
embryonically expressed protein Noggin to inhibit BMP signaling, 
generating neural progenitors from hPSCs with high efﬁciency (33). 
More recent protocols replace Noggin by small molecule inhibitors 
of BMP signaling, most commonly dorsomorphin or LDN193189 
(94, 146, 178). In fact small molecules have been uni- versally 
adopted for the directed differentiation of hPSCs as they 
demonstrate potent efﬁcacy and are more cost effective compared 
to recombinant proteins (130). Dual SMAD inhibition is now the 
“gold standard” for the generation of neural progenitors from hPSCs 
and has been used to produce a diverse range of both neu- rons and 
astrocytes (105). 
Once neural progenitors are speciﬁed, it is advantageous that 
these are expandable in culture. In vivo, embryonic neural progen- 
itors are required to be highly proliferative to enable generation of 
the large numbers of neural cells within the adult CNS. Similarly 
in vitro this means that only a small starting number of hPSCs are 
required to generate large numbers of mature cells. In the devel- 
oping embryonic CNS progenitor populations proliferate in 
response to ﬁrst FGF and later to EGF signaling (29, 60). There- 
fore, the addition of these mitogens to hPSC derived neural pro- 
genitors to drive expansion has become commonplace (46, 90, 
93, 105). However, some hPSC differentiation protocols do not 
require the addition of mitogens for proliferation of the neural 
progenitors, and it is presumed that in these systems the progeni- 
tors produce autocrine signals to induce proliferation (33, 94). 
However, addition of exogenous mitogens can enable hPSC 
derived neural progenitors to proliferate in vitro culture for longer 
periods (46, 90, 93, 105) (Table 1). 
  
Table 1.  Astrocyte differentiation from human  induced  pluripotent stem cells. 
 
Brain region Patterning 
factors 
Astrogliogenic 
factors 
Initial 
differentiation 
Method of 
differentiation 
Timings required 
from hPSC/yield 
Markers 
determined 
References 
Various FGF8A, None EB EB are plated  onto  culture  sur- 180d S100b/GFAP/ Krencik et al, 2011 
 RA   face  & neural  rosettes >90% GFAP, S100b Aldh1L1  
 SHH   undergo physical  selection &    
    expanded as nonadherent    
    spheres    
N/A None BMP2 EB EB cultured  in chemically 67d S100b/GFAP/ Gupta  et al, 2011  (67) 
  BMP4  defined  media.  At day 8 neu- >95% GFAP AQP4/EAAT1  
  LIF  ral progenitors then  plated    
    onto  culture  surface and    
    expanded (1EGF1FGF21    
    Heparin).    
Ventral spinal RA LIF Monolayer Dual SMAD inhibition on mono- >56d Vimentin/ Serio et al, 2013  (149) 
cord Purmorphamine CNTF  layer hPSCs.  Neural progeni- >90% S100b, GFAP S100b/GFAP  
    tors  expanded as  nonadherent    
    neurospheres (1EGF1LIF fol-    
    lowed  by 1EGF1FGF).    
Ventral spinal RA CNTF Monolayer Dual SMAD inhibition on mono- 80–100d S100b/GFAP Roybon  et al, 2013  (146) 
cord SHH FBS  layer hPSCs.  Neural progeni- 
tors  expanded in commercial 
rv100%  S100b CX43/Aldolase-C/ 
EAAT2 
 
    media    
N/A None BMP2 Monolayer Neural progenitors differentiated 52d GFAP/S100b/ Majumder et al, 2013  (112) 
  LIF  from hPSCs  as an adherent Majority GFAP (not quantified) EAAT1/ALDH1L1  
  Trichostatin  A  monolayer.    
  Aza-cytidine      
N/A None BMP4 EB!Monolayer EB are plated  onto  culture  sur- 
face  & neural  rosettes 
42d 
60%  S100b 
GFAP. Vimentin, S100b Chen  et al, 2014  (36) 
    undergo physical  selection &    
    expanded as nonadherent    
    spheres    
N/A CHIR99021 
SHH 
LIF 
FBS 
EB!Monolayer Dual SMAD inhibition during EB 
formation. Neural rosettes  iso- 
80d 
100% 
Vimentin/S100b/ 
GFAP/AQP4/EAAT2 
Palm et al, 2015  (129) 
    lated  as  neurospheres then    
    plated  onto  culture  surface    
    and expanded    
    (1EGF1FGF21LIF)    
N/A None None EB!Monolayer Dual SMAD inhibition during EB 
formation. Neural progenitors 
then  plated  onto  culture  sur- 
180d 
rv90%  GFAP, S100b 
GFAP/S100b Kondo et al, 2016  (90) 
face  and expanded 
(1EGF1FGF21Heparin) 
 
Abbreviations: d 5 days;  RA 5 retinoic  acid. 
  
 
 
 
 
Figure 1.  Differentiation and  patterning in the  developing CNS.  The 
CNS  develops  from   the   neural   tube   which   is  made  up  of  neural 
progenitor  cells.   In  the   early   embryo  neural   progenitors  can   only 
generate neurons and  only later  become capable of differentiating into 
glial  cells,   including  astrocytes. This  temporal  fate   switch  is 
recapitulated  in  vitro  in  both  ex  vivo  neural  progenitor cultures and 
also  in  the   differentiation  of  hPSCs.   Cells  within  the   CNS  acquire 
regional   identity   according  to   gradients  of  morphogens expressed 
across the  neural  tube.  The  rostrocaudal axis  is set  up  by a gradient 
of  retinoic  acid  (RA), which  is  highest where the  future   spinal  cord 
will form.  The  dorsoventral axis  is  set   up  by  opposing  gradients  of 
ventral  SHH signaling  and  dorsal  BMP  signaling.  These axes  facilitate 
the  correct spatial  patterning of the  developing CNS. 
 
Astrogliogenesis 
 
Astrogliogenesis refers to the generation of glial cells, in particular 
astrocytes, either in vivo or in vitro. In the embryonic brain neurons 
and astrocytes differentiate from the same neural progenitor pool. 
However, there is a distinct temporal shift from neuronal to glial 
fate acquisition (120) (Figure 1); initially neural progenitors are 
monopotent, generating neurons and only later become bipotent, 
differentiating into both neurons and glial cells, including astro- 
cytes (Figure 1). This temporal control is also recapitulated in vitro, 
in neural progenitor cultures ex vivo and in hPSC differentiation 
(93, 105), suggesting that fundamental intrinsic mechanisms con- 
trol the switch. The identiﬁcation of a single speciﬁc cue that indu- 
ces the neuron-to-glial fate switch remains elusive, but research has 
uncovered a number of essential signaling pathways (120). In rela- 
tion to hPSC differentiation, astrocytes will differentiate from hPSC 
derived neural progenitors by ‘default’ after elongated peri- ods in 
culture (90, 93, 105). For a cell population highly enriched for 
astrocyte culture periods of over 180 days are required (90, 93). 
Therefore, factors to promote the glial fate switch and astrocyte dif- 
ferentiation are frequently added to protocols to reduce culture 
times and increase the yield of astrocytes. A classic approach for 
generating astrocytes from ex vivo neural progenitors was to add 
animal serum to the culture media (137). This approach has also 
been used successfully with hPSC derived neural progenitors (100, 
129, 146). However, an undeﬁned component like animal serum 
could lead to lack of reproducibility and other unwanted effects on 
the neural cells, particularly when using hPSC derived neural cells 
for disease modelling. Therefore, researchers have looked to astro- 
gliogenesis in the embryo for candidate molecules and signaling 
pathways that could be utilized to promote the generation of astro- 
cytes (105). 
In particular the Interleukin-6 (IL-6) family of cytokines including 
Ciliary Neurotrophic Factor (CNTF), Leukemia Inhibitory Factor 
(LIF) and Cardiotrophin (CT-1) promote the generation of astrocytes 
via induction of downstream JAK-STAT signaling (21, 71). Acti- 
vated JAK (Janus Kinases) tyrosine kinases in turn activate Signal 
Transducers and Activators of Transcription (STAT) proteins which 
function as transcriptional activators at astrocyte speciﬁc loci, such 
as GFAP and S100b (21, 71). LIF and CNTF are frequently used in 
the generation of astrocytes from hPSCs (149) (Table 1). One study 
by Serio and colleagues generated astrocytes from hiPSCs as part of 
an in vitro model of CNS proteinopathy. They achieved over 91% 
GFAP positive cells from multiple hiPSC lines using an approach of 
extended expansion of hiPSC derived neural progenitors in the pres- 
ence of EGF and LIF, followed by terminal astrocytic differentiation 
with CNTF. The period of expansion required was much reduced 
compared to na€ıve generation (93, 149). 
Clearly the IL-6 family of cytokines and subsequent JAK-STAT 
signaling is crucial to initiation of astro gliogenesis. However high 
levels of JAK-STAT signaling alone cannot override the program 
for the initial generation of only neurons (21, 71, 75), indicating 
that the neuron to astrocyte switch is controlled by multiple mecha- 
nisms. BMP and NOTCH signaling also synergistically promote 
astrocyte differentiation, but only in the presence of active IL6/ 
JAK-STATs (62, 75, 84, 124, 125). BMP signaling is context spe- 
ciﬁc; in early CNS development it promotes the generation of neu- 
rons and only in the later gliogenic period do BMPs promote the 
differentiation of astrocytes (99, 108, 159). BMP downstream sig- 
nal  transducers, the  SMAD  proteins  interact  with  the  CREB- 
  
 
 
Table 2.  Disease Phenotypes in hiPSC-derived  astrocytes. 
 
Disease Gene  Findings  References 
 
Alexander’s 
Disease 
 
GFAP GFAP aggregates (Rosenthal like fibers) 
Compromised cell adhesion 
 
"Il-5 "Il-
6 "TNF-
/ 
"mTOR  signaling 
 
Kondo et al, 2016  (90) 
ALS  TARDBP
M337V      
"Cell toxicity 
#Astrocyte survival 
TARDBP
M337V     
"Cytoplasmic TDP43 levels 
# Astrocyte survival 
Barmada et al, 2014  (11) 
Cell autonomous effect Serio et al, 2013  (149) 
SOD1 
C90RF72 
Sporadic 
"CRX43 expression 
"Astrocyte Coupling? 
Almad et al, 2016  (4) 
Alzheimer’s APP V717I Single-Cell secretion profiling Significant  astrocytic Ab secretion   Liao et al, 2016  (101) 
Disease PSEN
M146L 
ApoE4
1/1
 
Aberrant  morphology 
Astrocytic  atrophy 
#S100b #EEAT1 #GS 
Conditioned medium 
"CCL5, "MIP-1b 
#IL-8 #MCP-1 
Jones et al, 2017  (82) 
Down’s Syndrome   21 Trisomy  " S100b astroglia  differentiation 
"Proliferation 
#Nrf2 #BDNF #ApoE 
" iNOS "ROS 
 
FTD  MAPT
N279K 
Enlarged  astrocytes 
"Oxidative damage sensitivity 
"Protein degradation 
Conditioned medium 
#Neurogenesis 
#Neurite  outgrowth 
#Neuron  maturation 
#Synapse formation 
"S100b 
"ANXA2 
"NPY 
"MAOB 
Chen  et al, 2014  (36) 
 
 
 
 
Hallman et al, 2017  (69) 
HD  HTT Astrocyte Vacuolization  Juopperi et al, 2012  (83) 
Rett Syndrome  MeCP2
R294
* " Microtubule growth 
" Microtubule transport 
" Non-directional  lysosomal movement 
#Acetylated /-tubulin Dele'pine et al, 2016  (47) 
MeCP2
V247
* 
MeCP2
R294
* 
MeCP2
R306C 
Co-culture 
#Neurite  length 
#Neurite  number 
#EPSCs 
Conditioned medium 
#Neurite  length 
#Neurite  number 
#EPSCs 
Williams et al, 2014  (170) 
SMA SMN1  "Catalase 
#ROS levels 
SMN1  "GFAP 
#Astrocytic  processes 
"Resting Ca
21  
levels 
"# Respiration 
"#MnSOD, Nrf2 
#GDNF 
#ATP-induced  Ca
21  
response 
Patitucci  et al, 2016  (132) 
McGivern  et al, 2013  (116) 
X-linked ALD  ABCD1 "Il-6 Baarine  et al, 2015(8) 
 
Abbreviations: ALS 5 amyotrophic lateral sclerosis; FTD 5 frontotemporal dementia; SMA 5 spinal muscle atrophy;  ALD 5 adrenoleukodystrophy. 
 
 
binding protein (CBP)/p300 transcriptional activator complex, acti- 
vating genes containing a CBP binding site in their promoter region. 
Nakashima et al, demonstrated that CBP/p300 further com- plexes 
with the STAT protein STAT3, downstream of the IL-6 cytokine 
pathway, resulting in direct activation of astrocyte genes including 
GFAP (124). Accordingly the pro-astrocytic properties of animal 
sera are attributed to BMP2 and BMP4 (79). In terms of hPSC 
differentiation, BMPs are often used together with the IL-6 family 
cytokines to synergistically enhance astrocyte generation as they do 
in the developing CNS (67). Gupta and colleagues demon- strated 
  
that co-application of BMP4 and LIF signiﬁcantly increased the 
generation of functional astrocytes from human ESCs (67). In this 
study, a combination of BMP4 and LIF generated over 95% GFAP 
positive cells in 67 days. Similar approaches have now been applied 
to hiPSCs for the highly efﬁcient generation of astrocytes for 
disease modeling (16). 
Notch signaling is another context speciﬁc regulator of astroglio- 
genesis; during neurogenesis Notch signaling acts to maintain the 
neural progenitor pool. Like BMP signaling, Notch is only able 
to induce astrogliogenesis if JAK-STAT signaling is active (62, 
84). Notch signaling leads to transcription of the Hairy Enhancer 
of Split (Hes) gene and the Hes protein then binds to active JAK 
and STAT proteins and forms complexes which also act as tran- 
scriptional activators (62, 84). Notch activation increases expres- 
sion of GFAP as the GFAP promoter contains Notch responsive 
elements (62). 
From our knowledge of the role of Notch signaling in astro glio- 
genesis it is logical that the Notch pathway could be exploited for 
astrocyte generation from hPSCs (37, 126). Accordingly the inhibi- 
tion of Notch signaling is commonly used to increase the efﬁciency 
of neuronal differentiation from hPSCs via use of the g-secretase 
inhibitor N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-S-phenyl-glycine 
  
 
 
t-butyl ester (DAPT) (20, 22, 94). However, the multiple roles of 
Notch signaling in the development of the CNS make this a difﬁ- 
cult pathway to target. One study by Emdad et al, attempted to dif- 
ferentiate astrocytes from hPSCs by stimulating Notch signaling in 
combination with CNTF but saw no pro-astrocytic effect on gene 
expression (51). However, this is a single study and this result is in 
direct disagreement with work on ex vivo rat embryonic neural pre- 
cursors, where Notch activation in the presence of CNTF increased 
generation of astrocytes compared to CNTF alone (122). This may 
be down to the different methods of Notch activation used in the 
two studies, species differences, or other differences in culture con- 
ditions, but the targeting of Notch signaling for the generation of 
human astrocytes does warrant more investigation. 
As with all cellular differentiation, the generation of astrocytes is 
under the restraint of epigenetic remodelling. The temporal fate 
shift of neural progenitors results from changes at neuronal vs glial 
gene loci, causing downregulation of pro-neuronal genes and 
upregulation of astrocyte genes (21, 56, 71, 75). This is ultimately 
achieved by epigenetic changes in parallel and in conjunction with 
the discussed signaling pathways. DNA methylation blocks the 
binding of STAT proteins and the activation of astrocytic genes 
during early CNS development; conversely global inhibition of 
DNA methylation enables premature astrocyte differentiation via 
JAK-STAT signaling activating the demethylated and therefore 
permissive astrocytic gene loci (21, 56, 71, 75). Notch signaling 
also acts directly on the epigenetic status of multiple astrocytic gene 
promoters; Namihira and colleagues demonstrated that active Notch 
signaling induces demethylation of the promoter via binding of the 
NFIA transcription factor (126). NFIA acts by protecting the 
promoter from  methylation  by  DNA  Methyltransferase 1 
(DNMT1) and the resulting demethylation enables transcriptional 
activators, such as the STATs, to bind to these promoters and 
induce gene expression (126). For this reason activation of Notch 
signaling is also a prerequisite for the ability of JAK-STAT pro- 
teins to induce astrocytic gene expression, but it cannot promote 
astrocyte differentiation without JAK-STAT signaling (37, 126). 
An alternative approach to generate astrocytes would be to 
directly modulate the epigenetic status of hPSC or the hPSC derived 
neural progenitors. Inducing a “glial-permissive” epigenetic 
landscape could prematurely induce astrogliogenesis, and further 
reduce required culture time. One study by Majumber et al used 
the DNA methyltransferase inhibitor Aza cytidine, and the histone 
deacetylase inhibitor Trichostatin-A, in combination with BMP2 
and LIF on hPSC derived neural progenitors (112). They reported 
reduced methylation and increased acetylation of astrocytic gene 
promoters, including that of GFAP and S100b compared to 
untreated controls, and correspondingly the premature appearance 
of astrocytes (112). In support of this pharmacological epigenetic 
modiﬁcation has shown comparable effects on rodent neural pro- 
genitors in vivo and in vitro (150, 160). Off target effects prevent 
these approaches from being adopted more widely. Indeed, such 
treatments lead to widespread cell death (112) and may have an 
impact on any disease phenotype. 
It is clear that as in the developing brain astrocytes differentiate 
in vitro from hPSC derived neural progenitors following a default 
developmental timeline. Studies that have achieved high astrocyte 
yields without the addition of extrinsic factors tend to require much 
longer time periods in culture (90, 93) (Table 1). In vivo there is a 
requirement for the presence of differentiating neurons to induce 
astrocyte differentiation, as neurons are the source of Notch ligands 
(37, 126) and CT-1—a member of the IL-6 family—which induces 
JAK-STAT activation (12). This may explain in part why neuro- 
genesis and astrogliogenesis happen in a sequential manner. There- 
fore most popular strategies to decrease differentiation time in vitro 
and increase efﬁciency of astrocyte differentiation are to target 
these pathways required in the embryo, to an extent substituting for 
the required presence of neurons (Table 1 and references within). 
 
Regional identity and astrocyte function 
 
Another requirement for cellular specialization within the CNS is 
acquisition of regional identity. In the embryo, the neuroepithelium 
starts as a plate-like structure which then folds and fuses to forming 
the neural tube. The neural tube develops both rostrocaudal and dor- 
soventral axes, which provide the outline for the spatial patterning 
required to generate the different regions of the mature CNS (Figure 
1). The axes are set up by gradients of speciﬁc morphogens. The 
rostrocaudal axis is set up by a gradient of retinoid signaling via 
Retinoic Acid (RA), highest in the caudal extreme where the future 
spinal cord will form (162) (Figure 1). The dorsoventral axis is 
regulated by Sonic Hedgehog (SHH), expressed ventrally along the 
length of the neural tube, and BMP signaling, highest at the dorsal 
side of the neural tube (162) (Figure 1). Both neurons and astrocytes 
possess regional speciﬁc identity and consequently express region 
speciﬁc markers (31, 93). Regional identity is key to function, phe- 
notype and even the morphology of neural cells. The importance of 
regional identity to neuronal function is historically well docu- 
mented, but only more recently it has been recognized that the 
regionalization of astrocytes is similarly integral to their function 
(31, 44, 93). This relates to their effective support of the speciﬁc 
neuronal populations within that region (13, 31, 44, 92, 93, 95, 136, 
176). For example, astrocytes in the cortex cannot provide the 
trophic support required by midbrain neurons (44). Therefore, when 
generating astrocytes from hPSCs for in vitro study or transplanta- 
tion, we must accurately assign this regional identity. Researchers 
are now able to generate a vast array of regionally patterned neuro- 
nal cell types, for example, cortical glutamatergic, ventral forebrain 
cholinergic, ventral midbrain dopaminergic and cholinergic motor 
neurons (48, 93, 94, 105, 151). The same principles are now being 
combined with our knowledge of astrocyte development, to gener- 
ate regionally patterned astrocytes (see Table 2). 
This is achieved by treatment with developmental molecules, in 
particular the aforementioned, RA, BMPs and SHH, thus recapitu- 
lating signaling in the developing CNS (105) (Table 1). A seminal 
study by Krencik et al, demonstrated that regionalized astrocytes 
and neurons could be generated from the same pool of hPSC 
derived neural progenitors. Krencik and colleagues demonstrated a 
universal protocol that could be ‘ﬁne-tuned’ by the addition of such 
morphogens to the hPSC derived neural progenitor pool (93). The 
progenitors retained this patterning even after the 180 day expan- 
sion period required for the appearance of astrocytes (93). These 
astrocytes correctly recapitulated regional identities spanning the 
rostrocaudal and dorsoventral axes of the CNS (93). For example, 
addition of SHH resulted in expression of the ventral forebrain tran- 
scription factor NKX2.1 in S100b1  astrocytes, whereas addition of 
RA resulted in expression of caudal transcription factor HOXB4 
(93). Roybon et al used a similar approach to successfully generate 
ventral spinal cord astrocytes by combined addition of SHH and 
  
 
 
RA (146). These ﬁndings agree with the regional astrocytic pheno- 
types seen in vivo and highlight how crucial generating regional- 
speciﬁc astrocytes is for accurate disease modeling (31, 44, 176). 
 
STANDARDIZATION AND FUNCTIONAL 
CHARACTERIZATION 
 
A major issue when generating any cell type from hPSCs is suitable 
phenotypic and functional characterization. It is absolutely crucial 
that the stem cell ﬁeld adopts a standardized and multifaceted strat- 
egy to characterize hPSC derived cells, because this will enable 
direct comparison of derivation methods and the resulting cells. 
One cannot model a disease without the bona ﬁde cell type that 
the speciﬁc disease affects in vivo, and clearly these cells must be 
functional if we are to determine how function is affected in dis- 
ease. In terms of neural differentiation, we are starting to see a set 
of standard characterization methods emerge. Here we will discuss 
those required for characterization of hPSC derived astrocytes, and 
how this may impact the ﬁeld. 
As discussed astrocytes are a very heterogeneous cell type and 
this diversity extends to their morphology and expression of what 
are classed as “typical” astrocyte proteins such as GFAP or S100b 
(176). If we just compare the morphology of the two crude astro- 
cytic subclasses, they are remarkably different. When we think of 
the classical “star-like” astrocytes these are in fact ﬁbrous astro- 
cytes. In comparison protoplasmic astrocytes have a more irregular, 
‘bushy’ appearance, extending long sheet-like processes (117, 118, 
128). The morphology of astrocytes also changes depending on 
their proliferative or reactive status (14, 128). Furthermore, astro- 
cytes differentially express GFAP, which is traditionally considered 
and still used by many as the ﬁrst line astrocytic marker. Protoplas- 
mic astrocytes generally express GFAP at much lower levels than 
ﬁbrous astrocytes and high levels of GFAP are also a feature of 
reactive astrocytes (118, 128). This heterogeneity therefore makes 
the identiﬁcation of astrocytes both in vivo and in vitro very difﬁ- 
cult and this also translates identifying astrocytes generated from 
hPSCs. What is the best strategy to conﬁrm and evaluate the gener- 
ation of astrocytes form hPSCs? 
A seminal study by Cahoy et al has contributed a range of novel 
astrocyte speciﬁc markers. Transcriptome analysis compared astro- 
cytes, neurons and oligodendrocytes from early vs. late postnatal 
mouse forebrain (28). Two markers in particular, ALDH1L1 and 
Aldolase-C were shown to be astrocyte speciﬁc (28). Antibodies for 
detection of these markers are commercially available and have been 
used for the identiﬁcation of astrocytes, including hPSC derived 
astrocytes (28, 52, 118) (Table 1). In addition the same study con- 
ﬁrmed astrocyte speciﬁc expression of Aquaporin-4 (AQP4), EAAT1 
(SLC1A3 or GLAST) and GFAP, along with S100b, which was used 
to identify astrocytes and oligodendrocytes (28). Therefore, we now 
have a library of conﬁrmed astrocytic markers that can be used in 
combination with cell morphology to better identify true astrocytes 
and distinguish them from other glial cell types. In addition these 
astrocytic markers can be used in combination with classical regional 
CNS markers to establish their regional identity (93). 
However, conﬁrmation of marker expression alone provides no 
information about astrocyte function. Particularly for disease mod- 
eling, derivation of astrocytes from hPSCs requires functional vali- 
dation. This is somewhat difﬁcult because we are still learning so 
much about astrocytes in vivo and their many functions in the brain 
(176). One of the main roles of astrocytes in vivo is to respond 
appropriately to neuronal signals including neurotransmitters such 
as glutamate or ATP, calcium ions and electrical signals (13). 
Astrocytic response can be measured by patch clamping individual 
astrocytes. However, more commonly hPSC-derived astrocytes are 
assessed by calcium imaging. These stimuli result in changes in 
intracellular calcium stores, ﬂuorescent calcium dyes can be visual- 
ized and quantiﬁed in many cells simultaneously (92). This high 
throughout approach is advantageous when evaluating a large pop- 
ulation of astrocytes derived from hPSCs, and yields a more repre- 
sentative population picture. 
Glutamate uptake is another critical function of astrocytes, to 
reduce excitotoxicity from neuronal glutamate (92). As discussed 
reduced glutamate uptake is a feature of disease of the CNS, where 
it results in neuronal dysfunction and death (25, 63). In vitro gluta- 
mate uptake is typically measured by analysis of glutamate levels 
in cell media, which is now an easily accessible technique using 
commercially available kits. 
Another characteristic of astrocytes is their trophic role in the 
CNS. Astrocytes secrete neurotrophic factors such as GDNF (104) 
and Clusterin (44), which promote neuronal survival. Release of 
such molecules can be detected by multiple methods, and has been 
demonstrated in hPSC-derived astrocytes (173). Alternatively, neu- 
rotrophic function can be evaluated in co-culture with neurons, or 
with ‘astrocyte conditioned media’ by examining their affect on 
neurons (44, 92, 173). These methods enable in vitro dissection of 
the supportive role of astrocytes and how this may be altered in the 
disease state. 
One ﬁnal aspect of astrocyte function is their response to injury, 
disease and signals from the immune system, which can all result 
in a reactive phenotype. Reactive astrocytes are key to disease in 
the CNS and have been shown to have both beneﬁcial effects or to 
exacerbate the disease state. Therefore, we must be able to induce a 
reactive phenotype in vitro from hPSC derived astrocytes. This can 
inﬂuence all the aspects of astrocyte function we have discussed, 
but also has a key set of speciﬁc indicators. Induction can be 
achieved by many methods, including the addition of inﬂammatory 
cytokines (146) or introduction of toxins such as bacterial Lipo- 
polysaccharides (66). First, we must be able to identify reactive 
astrocytes and, one feature is upregulation of GFAP as well as 
changes in astrocyte morphology. In addition reactive astrocytes 
demonstrate expression of speciﬁc markers such as intercellular 
adhesion molecule-1 (ICAM-1) (3, 5) or LCN2 (174), and the 
secretion of inﬂammatory cytokines such as IL-6 (146). Roybon 
and colleagues successfully induced and identiﬁed reactive astro- 
cytes from hPSC derived cultures by exposing astrocytes to inﬂam- 
matory  cytokines,  which  induced  markers  of  reactivity,  and 
resulted in astrocytic secretion of IL-6 (146). 
It is crucial that detailed identiﬁcation and characterization crite- 
ria are applied to hPSC derived astrocytes. Together with the stand- 
ardization of protocols this will to allow proper comparison across 
disease modeling studies, and provide a framework for the possible 
therapeutic application of these cells. 
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